

JUBILANT PHARMA TRADING INC

Balance Sheet

As at 31st Mar	Notes No	2015 USD	2015 INR (* in Thousands)
I. EQUITY AND LIABILITIES			
Shareholders' Funds			
Share capital	1	100	6
Reserves & surplus	2	487,663	30,479
		487,763	30,485
Current liabilities			
Trade payables	3	4,786,769	299,173
Other current liabilities	4	281,452	17,591
Short-term provisions	5	262,588	16,412
		5,330,809	333,176
	Total	5,818,572	363,661
Current assets			
Current investments			
Inventories	6	1,248,756	78,047
Trade receivables	7	4,400,790	275,049
Cash & bank balances	8	88,701	5,544
Short-term loans and advances	9	80,325	5,020
		5,818,572	363,661
	Total	5,818,572	363,661

Prakash C Bisht

CFO (Ingredients) & Sr. VP (Group Accounts)

Place : Noida

Date : 29th April, 2015

JUBILANT PHARMA TRADING INC
Statement of Profit and Loss

For the year ended 31st March,	Notes No	2015	2015
		USD	INR (' In Thousands)
REVENUE			
Revenue from operations (Gross)	10	16,492,451	1,018,994
Total Revenue		16,492,451	1,018,994
EXPENSES			
Purchase of Stock-in-trade	11	16,622,040	1,025,627
CHANGE IN INVENTORIES OF FINISHED GOODS,WIP AND TRADED GOODS	12	(1,248,756)	(75,788)
Other expenses	13	366,732	22,606
Total expenses		15,740,017	972,445
Profit before tax		752,434	46,549
Tax Expenses			
- Current tax		264,771	16,383
Profit for the Year		487,663	30,167

Prakash C Bisht
CFO (Ingredients) & Sr. VP (Group Accounts)
Place : Noida
Date : 29th April, 2015

JUBILANT PHARMA TRADING INC
CASH FLOW STATEMENT

Cash flow Statement for the Year Ended	2015 USD	2015 INR (' In Thousands)
Cash flows from operating activities		
Net income before minority interest	752,434	46,549
Operating profit before working capital changes	752,434	46,549
Adjustments for :		
(Increase)/Decrease in trade and other receivables	(4,481,115)	(280,070)
(Increase)/Decrease in inventories	(1,248,756)	(78,047)
Increase/(Decrease) in trade and other payables	5,066,038	316,627
A. Cash inflow/(outflow) in course of operating activities	88,601	5,060
B. Cash flow arising from financing activities :		
Proceeds from issue of share capital(including share premium & net of share issue expenses)	100.00	6
Net cash inflow/(outflow) in course of financing activities	100	6
C. Foreign currency translation difference arising on consolidation		478
Net Increase in cash & cash equivalents (A+B+C)	88,701	5,544
Cash & cash equivalents at the close of the year(including balance in dividend accounts)	88,701	5,544

Notes:

1) Cash Flow Statement has been prepared under the indirect method as set out in Accounting Standard 3 (AS-3)- "Cash Flow Statements"

Prakash C Bisht

CFO (Ingredients) & Sr. VP (Group Accounts)

Place : Noida

Date : 29th April, 2015

JUBILANT PHARMA TRADING INC
Notes to the Financial Statements

As at 31st Mar	2015	2015
	USD	INR (' In Thousands)
1. SHARE CAPITAL		
Authorized		
Equity Share Capital (3,000 common stock with no par value)	-	-
Issued & Subscribed		
Equity Share Capital [101 shares fully paid up]	100	6
	100	6
Paid up		
Equity Share Capital [101 shares fully paid up]	100	6
	100	6

1.1) The Company has only one class of shares referred to as equity shares having par value of USD 1 each. Each holder of equity shares is entitled to one vote per share.

1.2) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company, after distribution of all preferential amounts. However, no such preferential amounts exist currently. The distribution will be in proportion to the number of equity shares held by the shareholders.

3) The details of shareholders holding more than 5% shares in the company

As at 31st March	2015	2015
Name of the shareholder	USD	INR (' In Thousands)
Jubilant Pharma Holding INC-the Holding Company	100	100.00%

4) The reconciliation of the number of shares outstanding as at beginning and at the end of reporting period

As at 31st March	2015	2015
Name of the shareholder	No.	'INR (' In Thousands)
Numbers of shares at the beginning	-	-
Add: Shares issued during the year	101	6
Numbers of shares at the end	101	6

5) Shares held by holding company/ultimate holding company and/or their subsidiaries/associates

Out of the equity Shares issued by the company, shares held by it's holding company/ultimate holding company and/or their subsidiaries/associates are as below:

As at 31st March	2015	2015
Particulars	No.	'INR (' In Thousands)
Jubilant Pharma Holding INC-the Holding Company	101	6.25

JUBILANT PHARMA TRADING INC
Notes to the Financial Statements

As at 31st Mar	2015	2015
Particulars	USD	INR (' In Thousands)
2. RESERVES AND SURPLUS		
Foreign Currency Translation Reserve		
Foreign Currency Translation Reserve During the Year	-	312
	-	312
Surplus as per P&L Account		
Add: Net Profit after tax transferred from Statement of Profit and Loss	487,663	30,167
	487,663	30,479
3. TRADE PAYABLES		
Trade payables-others	4,786,769	299,173
	4,786,769	299,173
4. OTHER CURRENT LIABILITIES		
Trade deposits & advances	279,140	17,446
Statutory dues	2,183	136
Other payables	129	8
	281,452	17,591
5. SHORT TERM PROVISIONS		
Provision for income tax & wealth tax	262,588	16,412
	262,588	16,412
6. INVENTORIES		
Stock-in-trade	1,248,756	78,047
	1,248,756	78,047
7. TRADE RECEIVABLES		
Unsecured,considered good	4,400,790	275,049
	4,400,790	275,049
8. CASH AND BANK BALANCES		
Balances with banks:		
- On current accounts	88,701	5,544
	88,701	5,544
9. SHORT TERM LOANS AND ADVANCES		
- From related parties	80,325	5,020
	80,325	5,020
10. REVENUE FROM OPERATIONS		
Sales of products	16,492,451	1,018,994
	16,492,451	1,018,994
11. PURCHASES OF STOCK IN TRADE		
Purchase of stock-in-trade	16,622,040	1,025,627
	16,622,040	1,025,627
12. CHANGE IN INVENTORIES OF FINISHED GOODS,WIP AND TRADED GOODS		
Stock at close	1,248,756	75,788
-Traded goods		
	1,248,756	75,788
13. OTHER EXPENSES		
Traveling & other incidental expenses	13,643	849
Printing & stationery	364	22
Legal , professional & consultancy charges	225,000	13,859
Freight & forwarding (including ocean freight)	92,967	5,730
Bank Charges	586	36
Discounts & claims to customer and other selling expenses	34,173	2,110
	366,732	22,606